Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Pfizer and Roivant launch autoimmune specialist Priovant

US panel backs Omicron-targeting vaccines for booster campaigns

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

NHS App could offer video consultations by 2024

Novartis will shed 7% of workforce in restructuring, say reports

NBE-Therapeutics

Boehringer Ingelheim, Biberach, Germany, February 2007

News/ News/ Oncology

Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

Phil Taylor antibody-drug conjugate, Boehringer Ingelheim, M&A, NBE-Therapeutics, Oncology, triple negative breast cancer 0 Comment

Boehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics,

X

Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

https://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/

exelixis

News/ News/ Oncology/ Top stories

Exelixis doubles down on ADCs for cancer with NBE, Catalent deals

Phil Taylor antibody-drug conjugate, Catalent, Exelixis, licensing, NBE-Therapeutics, Oncology 0 Comment

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug

X

Exelixis doubles down on ADCs for cancer with NBE, Catalent deals

https://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Ipsen beefs up in oncology, buying US biopharma Epizyme
GSK hepatitis B hope bepirovirsen heads for phase 3 test
Novartis will shed 7% of workforce in restructuring, say reports
Another Astellas gene therapy hits a safety hurdle
BioMarin gene therapy for haemophilia on course for EU approval

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com